Share on StockTwits

Alexion Pharmaceuticals (NASDAQ:ALXN) CEO Leonard Bell unloaded 70,000 shares of the company’s stock in a transaction dated Friday, August 15th. The stock was sold at an average price of $167.99, for a total value of $11,759,300.00. Following the sale, the chief executive officer now directly owns 1,027,186 shares of the company’s stock, valued at approximately $172,556,976. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Shares of Alexion Pharmaceuticals (NASDAQ:ALXN) traded down 0.62% during mid-day trading on Monday, hitting $170.24. The stock had a trading volume of 1,177,237 shares. Alexion Pharmaceuticals has a one year low of $100.89 and a one year high of $185.43. The stock has a 50-day moving average of $162.5 and a 200-day moving average of $162.6. The company has a market cap of $33.676 billion and a P/E ratio of 85.86.

Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its quarterly earnings results on Thursday, July 24th. The company reported $1.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.07 by $0.05. The company had revenue of $512.50 million for the quarter, compared to the consensus estimate of $509.54 million. During the same quarter last year, the company posted $0.73 earnings per share. Alexion Pharmaceuticals’s revenue was up 38.5% compared to the same quarter last year. Analysts expect that Alexion Pharmaceuticals will post $5.01 EPS for the current fiscal year.

A number of analysts have recently weighed in on ALXN shares. Analysts at Nomura reiterated a “buy” rating on shares of Alexion Pharmaceuticals in a research note on Friday, July 25th. They now have a $224.00 price target on the stock, up previously from $222.00. Separately, analysts at Stifel Nicolaus reiterated a “buy” rating on shares of Alexion Pharmaceuticals in a research note on Friday, July 25th. They now have a $222.00 price target on the stock, up previously from $220.00. Finally, analysts at JPMorgan Chase & Co. reiterated an “overweight” rating on shares of Alexion Pharmaceuticals in a research note on Friday, July 25th. They now have a $220.00 price target on the stock, up previously from $210.00. Five analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. Alexion Pharmaceuticals has an average rating of “Buy” and an average target price of $183.00.

Alexion Pharmaceuticals, Inc (NASDAQ:ALXN) is a biopharmaceutical company focused on serving patients with severe and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.